Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Anakinra (Primary) ; Tocilizumab (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Acronyms ESCAPE
- 08 Jan 2021 Status changed from active, no longer recruiting to completed.
- 04 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2020 Status changed from not yet recruiting to recruiting.